Background: Stroke is one of the leading causes of illnesses, affecting approximately 15 million people worldwide every year. A large amount of stroke patients are left with upper extremity paresis in the long term. Several studies have been made on the effect of Constraint Induced Movement Therapy …

In 2005,one of Schering-Plough's core products- Clarityne was approved by the Chinese State Food Drugs Administration (SDFA) from prescription pharmaceutical to OTC drug in the Chinese market.Together with the increasing awareness of health care of the Chinese citizens, it gave a great chance to Schering-Plough …